Krystal microplate enables development of drug testing assay
Scientists at the NCBS using Krystal 384-well black microplates to produce a standard drug testing assay for Plasmodium vivax infection.
Porvair Sciences reports that the National Center for Biological Sciences (NCBS) in Bangalore, India is using its Krystal 384 black microplate to produce a standard drug testing assay for Plasmodium vivax infection.
The NCBS is a leading national institute whose faculty members undertake research in the frontier areas of biology. Scientists at the NCBS use experimental and computational approaches to study molecules, cells and organisms creating an understanding of the biology at each of these levels to advance an integrated view of life processes.
In their research, the NCBS is using Krystal 384-well black microplates as the micro-environment to grow the cells infected with small numbers of parasites. Researchers are then treating the Krystal 384 black plates with different concentrations of drugs to check the effect on the infection and the development of the Plasmodium vivax parasites inside the cells.
Dr Mulaka Maruthi, a senior NCBS researcher commented "Because they are manufactured to a very high flatness tolerance the Porvair Sciences Krystal 384-well black plates are very convenient to use with both our inverted microscope and High Content Screening machine. The clear plate bottom permits direct microscopic viewing or HCS imaging and the images are of high resolution". Dr Maruthi added "Using the Krystal 384-well black plates we have been able to minimize the number of cells for seeding, use smaller numbers of parasites, and lower volumes of drugs. Overall the Krystal 384 black plate has enabled us to perform these experiments in a single plate instead of many 96 well plates or other well formats".
The Krystal 384-well microplate range incorporates novel square wells with a large liquid capacity of 120µl per well, increasing the achievable sensitivity of most HTS assays. Using a proprietary manufacturing technique, the Krystal 384 offers market leading plate flatness (+/- 0.1mm tolerance) that translates into a significant increase in measurement precision and elimination of read errors when performing cell based assays using fluorescent or luminescent imaging. All tissue-culture treated plates are supplied lidded and sterile, in individual bags.
Related News
-
News A Day in the Life of a Start-Up Founder and CEO
At CPHI we work to support Start-Up companies in the pharmaceutical industry and recognise the expertise and innovative angles they bring to the field. Through our Start-Up Programme we have gotten to know some of these leaders, and in this Day in the ... -
News Biopharmaceutical manufacturing boost part of new UK government budget
In their national budget announced by the UK Labour Party, biopharmaceutical production and manufacturing are set to receive a significant boost in capital grants through the Life Sciences Innovative Manufacturing Fund (LSIMF). -
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News Amgen sues Samsung biologics unit over biosimilar for bone disease
Samsung Bioepis, the biologics unit of Samsung, has been issued a lawsuit brought forth by Amgen over proposed biosimilars of Amgen’s bone drugs Prolia and Xgeva. -
News CPHI Podcast Series: Why we need to consider women in clinical trials
The latest episode of the CPHI Podcast Series with Lucy Chard covers women's health, specifically women's representation in clinical trials, the associated bias, and the impacts on health for this population. -
News US FDA does not approve MDMA therapy for PTSD, requests more data
The MDMA-based therapeutic developed by Lykos Therapeutics, a California-based Public Benefit Corporation (PBC), has been reviewed and unapproved by the US FDA. The regulator has requested additional phase III trial data for further safety and efficacy... -
News Novartis and Viatris latest facing lawsuit over HeLa cell misuse
Global pharmaceutical companies Novartis and Viatris are the latest hit with a lawsuit claim pertaining to alleged misuse of the ‘HeLa’ cell line from the estate of woman whose cancerous tissue cells were taken without consent. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance